Treatment of Retinal Degeneration in a Mouse Model for Dry AMD
Lewin's use of systemically deliverable therapeutic reagents is unique, and one of the compounds the team is testing has already been through Phase III trials for another disease involving nerve cells, namely Amyotrophic Lateral Sclerosis (ALS). The drug Lewin is testing is orally available and approved for human use.
If the research aims are successful, the team will take several steps to bring this information, and a potential dry AMD treatment, to patients. The first step would be to re-test the successful reagents in different AMD mice that are not directly related to RPE oxidative stress. Since preclinical information and human safety profiles are characterized for these compounds, this may accelerate bringing the drugs to clinical trial. In addition, if either class of compound shows promise, Lewin's team would initiate a collaboration with a medicinal chemist to modify the compounds for local delivery to the eye. Fortunately, there is a strong program in Medicinal Chemistry in the College of Pharmacy at the University of Florida, and these scientists already have a collaboration with Dr. Hendrik Luesch in that department.
First published on: Tuesday, July 10, 2012
Last modified on: Tuesday, September 3, 2013